Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ImmunoGen financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Stock Price
$31.2
2024-02-13
Market Capitalization
$8.7 B
2024-02-13
Revenue
$108.8 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|
| Revenue | 132.3M | 69.9M | 108.8M |
| Revenue growth, % | 60.8% | ||
| Cost of goods sold | 176.0K | ||
| Gross profit | 108.6M | ||
| Gross profit margin, % | 99.8% | ||
| General and administrative expense | 38.6M | 43.8M | 116.1M |
| Operating expense total | 154.7M | 194.9M | 329.5M |
| EBIT | (22.4M) | (125.1M) | (220.9M) |
| EBIT margin, % | -16.9% | -179.0% | -203.1% |
| Investment income | 729.0K | 51.0K | 4.3M |
| Interest expense | 95.0K | ||
| Pre tax profit | (139.3M) | (221.7M) | |
| Income tax expense | 1.2M | ||
| Net Income | (44.4M) | (139.3M) | (222.9M) |
| EPS | (0.2) | (0.7) | (0.9) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |